Mission Statement
Anthera Pharmaceuticals is a privately held pharmaceutical company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life–threatening inflammatory diseases.
Our Strategy
In order to efficiently commercialize its platform of potent anti-inflammatory products, Anthera has brought together a world-class development team with extensive experience in developing, licensing, and commercializing anti-inflammatory products for unmet medical needs.
Read More
Current Clinical Trials:
Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome
(IMPACTS Trial Site)
Fewer Recurrent Acute
coronary events with Near-term Cardiovascular Inflammation
Suppression
(FRANCIS Trial Site)
Press Releases
November 11‚ 2008
Anthera’s Varespladib Demonstrates Significant Anti-Inflammatory Effect And LDL Reduction In Patients With Coronary Heart Disease
September 24‚ 2008
Anthera Completes Special Protocol Assessment With FDA And Receives EMEA Scientific Advice On Development Path Toward Varespladib Approval
August 25‚ 2008
Anthera Pharmaceuticals Advances Global Development Strategy For Varespladib In Patients With Acute Coronary Syndrome With The Initiation Of Francis Trial
Anthera Raises Money for Children’s Hospital Oakland Research Institute.
Read More
Anthera has moved! Please note new address and phone number:
25801 Industrial Blvd, Suite B, Hayward, CA 94545 - (510) 856-5600